IPO Boutique

Kolltan Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Kolltan Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Kolltan PharmaceuticalsKLTN -
NASDAQ
TBD $0.00 $0.00TBD
Leerink Partners, Stifel
Co-Manager(s):
Guggenheim Securities, Janney Montgomery Scott
Filing(s):

Filed 2014-09-12



About Kolltan Pharmaceuticals (adapted from Kolltan Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases, or RTKs, for the treatment of cancer and other diseases with significant unmet need.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "KLTN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved